Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Paraproteinemias 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Leukemia, B-Cell 1Leukemia 1Immunoproliferative Disorders 1Immune System Diseases 1Hematologic Diseases 1Bronchiolitis Obliterans Syndrome 1Blood Protein Disorders 1

Interventions

Darbepoetin alfa 2piperine 1fludarabine phosphate 1ferrous sulfate 1ferric gluconate 1Whole-Body Irradiation 1Urination 1Therapeutics 1Sucrose 1Rituximab 1Phenytoin 1Peripheral Blood Stem Cell Transplantation 1Oxycodone 1Mycophenolic Acid 1Morphine 1Methotrexate 1Methadone 1Metformin 1KW-2478 1Hsp90 inhibitor KU757 1Granulocyte Colony-Stimulating Factor 1Gene Expression Profiling 1Fentanyl 1Fatty Acids, Omega-3 1Epoetin Alfa 1Early Intervention, Educational 1Cyclosporine 1Curcumin 1Celecoxib 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Monoclonal Gammopathy of Undetermined Significance × KW-2478 × Clear all
NCT01063907 2024-04-25

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Kyowa Kirin Co., Ltd.

Phase 1/2 Completed
95 enrolled 13 charts
LymphoidOther hematologic neoplasmPlasma cell

Bronchiolitis Obliterans Syndrome, Blood Protein Disorders, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias, Leukemia, B-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡